The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
AMSBIO has introduced recombinant Wnt3a with a new Wnt stabilizer that significantly extends the activity of this protein in serum-free medium from a half-life of just 2 hours to around 30 hours.
Read the rest of entry »
A second deal between Germany’s Boehringer Ingelheim and a UK firm has been announced this week, this time with Oxford-based Evox Therapeutics for a collaboration focused on exosome-mediated drug delivery.
Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.
Oxford, UK: Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.
New research published 14 December by the Association of the British Pharmaceutical Industry (ABPI) shows that the amount of capital invested alongside CVC into UK companies increased six-fold between 2010 and 2015, marking a fundamental shift in how start-up British biotech is funded.
AMSBIO announces iMatrix recombinant Laminin-511 E8 fragments, an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells.
Oxford Immunotec Ltd. and QIAGEN N.V. announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products.
Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus.
Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.